Pseudobulbar Affect (PBA)
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Syneos HealthNC - Morrisville
1 program1
dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mgPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Syneos Healthdextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg
Clinical Trials (1)
Total enrollment: 326 patients across 1 trials
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Start: Dec 2007Est. completion: Sep 2009326 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.